FindTrial
Sign In

SGLT2 Inhibitors increase the risk of urogenital infection in patients with type2 diabetes mellitus

An Observational Study To Evaluate The Association Between SGLT2 Inhibitors and Urogenital Infections In Patients Of Type 2 Diabetes Mellitus At a Tertiary Care Hospital - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/01/102589
Enrollment
152
Registered
2026-01-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E112- Type 2 diabetes mellitus with kidney complications

Interventions

Intervention1: Nil: Nil

Sponsors

Dr Ayush Mohan Tripathi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: written informed consent will be taken diabetes mellitus as per ADA criteria enrolled in OPD basis currently recieving SGLT2 inhibitors for atleast 4 weeks

Exclusion criteria

Exclusion criteria: patient with type 1 diabetes mellitus patient with known urogenital anatomical abnormality known immunocompromised state patient already on treatment for active urinary infection at the time of enrollment pregnancy

Design outcomes

Primary

MeasureTime frame
Incidence of urogenital infection in patient on SGLT2 inhibitorsTimepoint: baseline ,1month ,3month—

Secondary

MeasureTime frame
Identification of associated risk factor such as factors age ,sex ,glycemic control & comorbidities.Timepoint: Every month for 3 month—

Countries

India

Contacts

Public ContactDr Ayush Mohan Tripathi

Baba Raghav Das Medical college

ayusht622@gmail.com9839064457

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 7, 2026